BRAF and malignant colon neoplasm: However, the identified SNVs are more promising than other biomarkers because, unlike SNVs in KRAS and BRAF, they target the entire colon cancer population, including rectal cancer, and are not rare like BRAF, nor are they expensive like circulating tumor DNA.